Tags

Type your tag names separated by a space and hit enter

Eradication of Pseudomonas aeruginosa biofilms on cultured airway cells by a fosfomycin/tobramycin antibiotic combination.
Pathog Dis. 2013 Feb; 67(1):39-45.PD

Abstract

Chronic biofilm formation by Pseudomonas aeruginosa in cystic fibrosis (CF) lungs is a major cause of morbidity and mortality for patients with CF. To gain insights into effectiveness of novel anti-infective therapies, the inhibitory effects of fosfomycin, tobramycin, and a 4:1 (wt/wt) fosfomycin/tobramycin combination (FTI) on Pseudomonas aeruginosa biofilms grown on cultured human CF-derived airway cells (CFBE41o-) were investigated. In preformed biofilms treated for 16 h with antibiotics, P. aeruginosa CFU per mL were reduced 4 log10 units by both FTI and tobramycin at 256 mg L(-1) , while fosfomycin alone had no effect. Importantly, the FTI treatment contained five times less tobramycin than the tobramycin-alone treatment. Inhibition of initial biofilm formation was achieved at 64 mg L(-1) FTI and 16 mg L(-1) tobramycin. Fosfomycin (1024 mg L(-1)) did not inhibit biofilm formation. Cytotoxicity was also determined by measuring lactate dehydrogenase (LDH). Intriguingly, sub-inhibitory concentrations of FTI (16 mg L(-1)) and tobramycin (4 mg L(-1)) and high concentrations of fosfomycin (1024 mg L(-1)) prevented bacterially mediated airway cell toxicity without a corresponding reduction in CFU. Overall, it was observed that FTI and tobramycin demonstrated comparable activity on biofilm formation and disruption. Decreased administration of tobramycin upon treatment with FTI might lead to a decrease in negative side effects of aminoglycosides.

Authors+Show Affiliations

Department of Biology, Indiana University Purdue University Indianapolis, Indianapolis, IN 46202, USA. ga2@iupui.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23620118

Citation

Anderson, Gregory G., et al. "Eradication of Pseudomonas Aeruginosa Biofilms On Cultured Airway Cells By a Fosfomycin/tobramycin Antibiotic Combination." Pathogens and Disease, vol. 67, no. 1, 2013, pp. 39-45.
Anderson GG, Kenney TF, Macleod DL, et al. Eradication of Pseudomonas aeruginosa biofilms on cultured airway cells by a fosfomycin/tobramycin antibiotic combination. Pathog Dis. 2013;67(1):39-45.
Anderson, G. G., Kenney, T. F., Macleod, D. L., Henig, N. R., & O'Toole, G. A. (2013). Eradication of Pseudomonas aeruginosa biofilms on cultured airway cells by a fosfomycin/tobramycin antibiotic combination. Pathogens and Disease, 67(1), 39-45. https://doi.org/10.1111/2049-632X.12015
Anderson GG, et al. Eradication of Pseudomonas Aeruginosa Biofilms On Cultured Airway Cells By a Fosfomycin/tobramycin Antibiotic Combination. Pathog Dis. 2013;67(1):39-45. PubMed PMID: 23620118.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Eradication of Pseudomonas aeruginosa biofilms on cultured airway cells by a fosfomycin/tobramycin antibiotic combination. AU - Anderson,Gregory G, AU - Kenney,Thomas F, AU - Macleod,David L, AU - Henig,Noreen R, AU - O'Toole,George A, Y1 - 2013/01/10/ PY - 2012/08/07/received PY - 2012/11/08/revised PY - 2012/11/13/accepted PY - 2013/4/27/entrez PY - 2013/4/27/pubmed PY - 2013/11/13/medline SP - 39 EP - 45 JF - Pathogens and disease JO - Pathog Dis VL - 67 IS - 1 N2 - Chronic biofilm formation by Pseudomonas aeruginosa in cystic fibrosis (CF) lungs is a major cause of morbidity and mortality for patients with CF. To gain insights into effectiveness of novel anti-infective therapies, the inhibitory effects of fosfomycin, tobramycin, and a 4:1 (wt/wt) fosfomycin/tobramycin combination (FTI) on Pseudomonas aeruginosa biofilms grown on cultured human CF-derived airway cells (CFBE41o-) were investigated. In preformed biofilms treated for 16 h with antibiotics, P. aeruginosa CFU per mL were reduced 4 log10 units by both FTI and tobramycin at 256 mg L(-1) , while fosfomycin alone had no effect. Importantly, the FTI treatment contained five times less tobramycin than the tobramycin-alone treatment. Inhibition of initial biofilm formation was achieved at 64 mg L(-1) FTI and 16 mg L(-1) tobramycin. Fosfomycin (1024 mg L(-1)) did not inhibit biofilm formation. Cytotoxicity was also determined by measuring lactate dehydrogenase (LDH). Intriguingly, sub-inhibitory concentrations of FTI (16 mg L(-1)) and tobramycin (4 mg L(-1)) and high concentrations of fosfomycin (1024 mg L(-1)) prevented bacterially mediated airway cell toxicity without a corresponding reduction in CFU. Overall, it was observed that FTI and tobramycin demonstrated comparable activity on biofilm formation and disruption. Decreased administration of tobramycin upon treatment with FTI might lead to a decrease in negative side effects of aminoglycosides. SN - 2049-632X UR - https://www.unboundmedicine.com/medline/citation/23620118/Eradication_of_Pseudomonas_aeruginosa_biofilms_on_cultured_airway_cells_by_a_fosfomycin/tobramycin_antibiotic_combination_ L2 - https://academic.oup.com/femspd/article-lookup/doi/10.1111/2049-632X.12015 DB - PRIME DP - Unbound Medicine ER -